Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Integrated Phase II/III Randomized Study Comparing Durvalumab and Tremelimumab +/- Hepatic ArteriaL Infusion Chemotherapy With GEMOX in Hepatocellular Carcinoma With High Tumor burdEn

NCT06904170 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06904170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06904170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Integrated Phase II/III Randomized Study Comparing Durvalumab and Tremelimumab +/- Hepatic ArteriaL Infusion Chemotherapy With GEMOX in Hepatocellular Carcinoma With High Tumor burdEn
Lead sponsor
UNICANCER
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 14, 2025
Completion date
September 30, 2030
Enrollment
196 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma